SÃO PAULO, Brazil and
BOSTON, Aug. 24, 2021 /PRNewswire/ -- Dasa, the largest
integrated healthcare network in Brazil, has chosen to expand upon its
partnership with SOPHiA GENETICS SA (Nasdaq: SOPH) to offer the
first decentralized HRD (Homologous recombination deficiency)
analytics solution in Latin
America. HRD is a complex biomarker, important for PARP
inhibitors, that helps identify whether cancer patients may respond
better to specific treatments, and its use could ultimately lead to
personalized therapies that benefit the individual patient.
Renowned in Brazil and abroad,
Dasa serves more than 20 million patients per year – including
approximately 10% of the Brazilian population - through its more
than 250,000 medical partners comprised of more than 59 diagnostic
medicine brands and hospitals. With the help of the knowledge
pooling SOPHiA DDMTM platform, Dasa has drawn further
insights upon the many complex molecular datasets that they analyze
for the benefit of their patients.
Today's announcement further builds on the partnership that
began between the two companies in 2016, when Dasa chose SOPHiA
GENETICS to build the original workflow for its genomics lab. This
partnership further evolved when Dasa implemented SOPHiA
DDMTM Radiomics and Trial Match solutions in 2020
to create the first multimodal approach in the region. For
half a decade, the two companies have pioneered new ways to enable
scalability and high output screening on complex assays, shortening
the path from research to consumer applications and more.
"SOPHiA GENETICS' decentralized approach gives us automated and
reproducible results in-house. Their expert bioinformatics team got
us up and running on our own, helping us save considerable time,
gain efficiency, and offer a more affordable solution for
patients," said Gustavo Riedel,
Business Director for Genomics and LATAM Clinical Research at
Dasa.
"Dasa initially wanted to be able to track the entire diagnostic
journey for their cancer patients. With such a large regional
network, this is a task that's not unlike navigating an ocean of
data through a hurricane. Through our past collaborations – and now
the addition of our decentralized HRD solution - SOPHiA GENETICS is
able to act as the lighthouse that guides Dasa through the storm as
they make new discoveries, helping both short and long-term patient
care," said Jurgi Camblong, Co-founder and CEO of SOPHiA
GENETICS.
To learn more about how SOPHiA GENETICS data-driven insights are
improving diagnosis, treatment and drug development for patients
and the larger medical community, visit sophiagenetics.com.
About SOPHiA GENETICS:
SOPHiA GENETICS is a healthcare
technology company dedicated to establishing the practice of
data-driven medicine as the standard of care and for life sciences
research. It is the creator of the SOPHiA DDM™ Platform, a
cloud-based SaaS platform capable of analyzing data and generating
insights from complex multimodal data sets and different diagnostic
modalities. The SOPHiA DDM™ Platform and related solutions,
products and services are currently used by more than 780 hospital,
laboratory, and biopharma institutions globally.
More info: SOPHiAGENETICS.COM;
follow @SOPHiAGENETICS on Twitter
About Dasa:
Dasa is the largest integrated healthcare
network in Brazil, serving more
than 20 million people a year, with high technology, intuitive
experience and an attitude ahead of time. With more than 40
thousand employees and 250 thousand partner doctors, Dasa is the
healthcare solution that people want and that the world needs,
being present at every stage of care.
Dasa believes that in order to take care, it is always necessary
to take care fully. Therefore, it looks at health management in a
preventive, predictive and personalized way. It integrates
diagnostic medicine, hospitals, genomics, oncology, care
coordination, emergency care, telemedicine, clinical research and
science. In all, it has 15 reference hospitals (considering its own
network, inorganic growth and deals that are still under regulatory
approval), and more than 59 brands including diagnostic medicine
and hospitals, distributed in more than 900 units in Brazil.
Dasa guarantees agile, uncomplicated and friction-free
navigation of the health journey, for both patients and physicians
through its management platform, Nav. In addition, it offers
integrated and innovative corporate health solutions through Dasa
Empresas. We are Dasa and we are for life. For more information,
access: www.dasa.com.br.
Contact: sophiagenetics@consortpartners.com
View original
content:https://www.prnewswire.com/news-releases/dasa-expands-partnership-with-sophia-genetics-for-the-first-decentralized-cancer-biomarker-detection-solution-in-latin-america-301361074.html
SOURCE SOPHiA GENETICS